Novartis provides update on Phase III study evaluating investigational spartalizumab (PDR001) in combination with Tafinlar® + Mekinist® in advanced melanoma

  • Phase III COMBI-i trial did not meet primary endpoint for patients with advanced BRAF V600-mutated melanoma
  • Tafinlar + Mekinist remains an effective treatment option based on previously reported large, Phase III clinical trials1,2
     
  • Spartalizumab development program continues, investigating the immunotherapy in combination with other anti-cancer agents

Basel, August 22, 2020 — Novartis announced today that the Phase III COMBI-i study evaluating the investigational immunotherapy …

/by